Clinical phase II trial (NCT01975701) targeting FGFR1-TACC1 and FGFR3-TACC3 fusions and/or activating mutation in FGFR1, 2, or 3 by anti-tumor drug BGJ398 has been completed in December, 2015 for assessment of overall survival, anti-tumor activity, and safety and tolerability. Here, TACC1 is linked to neoplasm.